Home > About Us > Our Story
InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug discovery efforts.
An expert in CRISPR genome editing, InVivo Biosystems creates custom genome edited C. elegans and zebrafish models to enable aging and other disease studies. In addition, InVivo Biosystems provides in-vivo analytical services to produce data and insights for companies that need to make go/no-go decisions quickly in early-stage development of new compounds.
At InVivo Biosystems, we’re passionate about creating an inclusive workplace that encourages, supports and celebrates diversity. These are not just words for us – we actively seek to create an environment that reflects the global community we serve and where everyone feels empowered to bring their full, authentic selves to work.
We are scientists, researchers and barrier breakers. We are nature lovers, readers, hikers, artists, gardeners, sports enthusiasts, friends and family members – we are unique individuals. We believe diversity, equity and inclusion drive innovation. Together, we spark insights to create a better, healthier world.
University of Oregon Professor Shawn Lockery applied microfluidics techniques, which involve precise control and manipulation of constrained
NemaMetrix was one of the five finalists who received the award under the Obama Administration. The ScreenChip System was considered a disruptive
NemaMetrix adds the capability of creating custom CRISPR transgenics by joining forces with Knudra Transgenics, a pioneer and an expert in gene editing capabilities.
The company launches analytical services to produce data and insights for companies to de-risk preclinical development.
The company adds the capability of creating genetic models using zebrafish for understanding gene function, basic biology, and more precisely modeling human diseases.
While more than 2,000 companies applied for the opportunity to pitch at Demo Day, InVivo Biosystems (NemaMetrix) was one of 40 companies chosen to present at the A-ha!
The company adds phenotypic assay technologies specifically tailored to CNS diseases, such as epilepsy.
The company builds out a comprehensive drug discovery and development platform and identifies a set of lead therapeutics for the treatment of a variety of diseases.
The company appoints new executive level leaders and sets forth a new strategic vision for the journey of the RapidGen™ platform.
The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.
Built on a robust portfolio of CRISPR genome editing patents, InVivo Biosystems has established a comprehensive preclinical discovery and development platform. By leveraging alternative models and proprietary methods, we accelerate go-to-market timelines for pharmaceutical companies and beyond.
